Background: Domperidone is often used to promote lactation among women who have difficulty breastfeeding. Objective: To examine prescribing and dispensing practices of domperidone at the Women's and Children's Hospital (WCH), Adelaide. Methods: A retrospective audit of domperidone dispensing among women with singleton pregnancies who delivered at the WCH between January 2000 and July 2010 was undertaken. Women dispensed domperidone were identified using WCH pharmacy dispensing records. Maternal and infant clinical data were obtained from the WCH Perinatal Statistics Collection. An audit of paper-based medical records was undertaken for a random sample of 261 mother-child pairs to collect prescribing and additional clinical data. Results: From 2000 to 2010, 1605 women were dispensed domperidone. There was a steady increase in the percentage of women dispensed domperidone, from < 0.5% in 2000 to > 5% of total WCH pregnancies in 2010. Among women dispensed domperidone, the percentage of women who received > 1 dispensing remained consistent (20%) over time, as did the median number of days (12) from delivery to first dispensing. Multiparous women were more likely to receive domperidone within 3 days following delivery compared to primiparous women (8% vs 4%; P < .01). Most women (80%) received directions to take domperidone according to a standard tapering dosing regimen over 12 days. Notably, 60% of women had no documentation of being assessed by a lactation consultant. Conclusion: From 2000 to 2010, there was a considerable increase in domperidone dispensing. With a lack of clinical evidence to guide use, current practice appears to be based on anecdotal evidence.
Newly Expressed
The number of women who delivered at a major Australian tertiary teaching hospital and were dispensed domperidone as a galactogogue increased considerably from < 0.5% in 2000 to > 5% in 2010. Following a comparison to existing evidence, current practice appears to be based largely on anecdotal evidence, highlighting the need for well-designed randomized controlled trials. Grzeskowiak et al. 33 Background Despite the ability of the majority of mothers to be able to produce sufficient quantities of milk for their babies, given the correct support and information, insufficient milk supply, whether real or just perceived, is one of the most commonly reported reasons for discontinuation of infant breastfeeding. 1 Mothers who are particularly vulnerable to difficulties breastfeeding are those who deliver infants who are unwell and require supportive care following delivery, such as preterm infants. 2, 3 In many cases, these mothers are not directly able to breastfeed which, in addition to the stressful situation of having an unwell infant, can have a detrimental effect on milk supply. However, it is not only women of hospitalized infants who experience difficulty with lactation. Additional risk factors have been identified for difficulty initiating and/or maintaining milk supply including maternal illness, cesarean delivery, maternal smoking, previous breast surgery, mother-infant separation, and indirect lactation (ie, breast pump or manual milk expression). 2 Furthermore, anxiety, fatigue, and emotional stress in mothers can also contribute to breastfeeding difficulties. 4 Perceived milk insufficiency can occur as a result of a number of factors including normal postpartum physical breast changes, such as the softening of the breasts around 10-14 days postpartum, 2 or poor breastfeeding self-efficacy. 5 Breastfeeding self-efficacy is referred to as a mother's confidence in her own ability to breastfeed, 5 and it is influenced by numerous factors including prior breastfeeding experience, support from family and friends, and understanding of lactation physiology. 2, 5 Additionally, infant symptoms such as irritability, crying, and frequent feeding may all be misinterpreted as a lack of breast milk quality or quantity. 2 In situations of perceived milk insufficiency, nonpharmacological strategies such as education in correct infant positioning and attachment at the breast, increasing frequency of breastfeeds, and mechanical expression are usually sufficient to increase a woman's milk supply. 2, [6] [7] [8] However, in some situations, the use of nonpharmacological strategies is insufficient and some women still struggle to produce or maintain an adequate milk supply. Following the provision of adequate education regarding breastfeeding and an appropriate trial of nonpharmacological strategies, it may be necessary to consider pharmacological intervention with medications used to augment lactation, known as galactogogues. The most widely studied and commonly used galactogogues include the dopamine receptor antagonists metoclopramide and domperidone, which have both been demonstrated to be effective treatments for initiation and maintenance of lactation. 3, 4, 6, [9] [10] [11] [12] Both of these medications elicit their actions by blocking dopamine D 2 receptors in the anterior pituitary to stimulate prolactin release. A key difference between agents is that domperidone exerts its pharmacological effects in the peripheral nervous system (PNS), whereas metoclopramide acts centrally. 13 Although metoclopramide has been used extensively in the past, domperidone is preferred as it does not cross the blood-brain barrier and is associated with fewer central nervous system (CNS) side effects (ie, fatigue, irritability, depression) compared with metoclopramide. 2, 4, 7 In addition, domperidone is excreted only in small amounts (less than 0.01% of maternal weight-adjusted dose) into breast milk. 3 In Australia and a number of other countries, domperidone is approved for the treatment of nausea and vomiting and as a prokinetic agent, and use of domperidone as a galactogogue represents an "off-label" indication. In contrast, in the United States, domperidone is not approved for any indication, because of reported safety concerns. 14 These concerns relate to case reports of cardiac arrhythmia and sudden death among cancer patients receiving intravenous domperidone, 15 as well as evidence of reversible QT prolongation following oral administration of domperidone to neonates. 16 Although serious in nature, these safety concerns are regarded by some lactation experts as a gross overestimation of the risks associated with using domperidone. 14 Furthermore, although studies are rare, there appears to be growing evidence supporting the use of domperidone as a galactogogue. 14 In particular, a recent meta-analysis of a small number of randomized controlled trials of moderate to high quality demonstrated that domperidone is associated with a 75% increase in milk volume compared to placebo, with no reported maternal or neonatal adverse events. 14 Anecdotally, it has become more common in Australia in recent years to recommend that mothers with insufficient milk supply (whether real or just perceived) be prescribed domperidone to increase milk production and supply. In recognition of this trend, the Drug and Therapeutics Committee at the Women's and Children's Hospital (WCH), in South Australia, approved the use of a standardized "Domperidone Prescription Sheet for Increasing Milk Supply." This guideline was aimed at standardizing domperidone prescribing to a fixed dosetapering schedule over 12 days. This schedule consisted of 1 tablet (10 mg) 3 times a day for 5 days, followed by 1 tablet (10 mg) twice a day for 3 days, and then 1 tablet (10 mg) once a day for 4 days. Despite its approval and use since 2005, there are concerns that the standardized prescription regimen is based largely on anecdotal evidence rather than evidence from randomized controlled trials. Furthermore, there are concerns that the introduction of this regimen has led to an increase in the prescribing of domperidone, prior to adequate investigation into the effects of nonpharmacological interventions to increase milk supply, as well as variability in the time to treatment initiation. Hence, the use of domperidone in clinical practice is of interest. Therefore, the aim of this study was to undertake a retrospective audit of the use of domperidone as a galactogogue at a major Australian tertiary teaching hospital over a 10-year period.
Methods
This was a retrospective audit of medical and pharmacy records for women dispensed domperidone who delivered at the WCH in South Australia, Australia, between January 2000 and July 2010. The WCH is a specialist metropolitan tertiary-level teaching hospital and South Australia's largest maternity and obstetric service provider, caring for over 4000 pregnancies each year. The hospital is committed to supporting women wishing to breastfeed their newborns, and a number of support services are available to women in the average 3-5 days they stay in the hospital following delivery. In addition, following discharge from the hospital, all women who deliver at the hospital have access to a specialist breastfeeding unit (BFU). Women experiencing breastfeeding difficulties are admitted as day patients to the unit, which is staffed by midwives who are either lactation consultants or have extensive experience working with breastfeeding women.
The study used linkable health administrative data within the WCH, which included the WCH Perinatal Statistics Collection and the WCH Hospital Pharmacy Dispensing Records. Data relating to women dispensed domperidone were obtained from the WCH Pharmacy Dispensing Records, which contain data on all medications dispensed at the hospital from January 2000. Data available from the dispensing records include dispensing date, type of dispensing (ie, inpatient, outpatient), quantity supplied, and dispensing directions. The electronic dispensing records were then matched to all births recorded in the WCH Perinatal Statistics Collection, using each patient's unique hospital identifier number.
Women were included in the audit if they had delivered a singleton infant and received a prescription for domperidone within 6 months of the date of delivery. This step enabled an overall assessment and evaluation of the prescribing and dispensing trends for domperidone over the 10-year period. In addition to the overall assessment, an audit of paper-based medical records was undertaken for a random sample of mothers and their corresponding infants to obtain in-depth clinical data not available through use of linkable health administrative data. To obtain the random sample, women who had been dispensed domperidone were first stratified according to year of delivery. When the number of women dispensed domperidone in a particular year was less than 30, all women for that year were included in the medical record audit. When the number of women dispensed domperidone was greater than 30, a computer-generated random sample was selected. This resulted in a random selection of 261 corresponding mother-child pairs. Data collected from paper-based medical records included dose and duration of domperidone treatment, whether mothers saw a lactation consultant and/or were admitted to the BFU, and whether they directly requested domperidone.
Information on maternal age, race, smoking status, parity, infant birth weight, gestational age, and admission to hospital was obtained from the Perinatal Statistics Collection. Clinical Information Services at the WCH is responsible for maintaining the Perinatal Statistics Collection. Data are collected regarding the pregnancy and outcome of every live birth and late fetal death occurring at the WCH, including data on every infant admitted to the neonatal intensive care unit (NICU) and special care baby unit (SCBU). The data are collected according to the guidelines of the Pregnancy Outcome Unit of the South Australian Department of Health for the Supplementary Birth Records and in consultation with the senior clinicians at the WCH. The information in the Perinatal Statistics Collection has been previously validated and is reliable when compared with hospital case records. 17 The estimated length of gestational age at delivery is recorded in the Perinatal Statistics Collection and is based on the last menstrual period and ultrasound examination. Parity was defined as no previous deliveries (nulliparity) or 1 or more previous deliveries. Maternal race or ethnic group was classified as Caucasian, Asian, or other. Data on smoking are routinely collected during the first antenatal visit and therefore reflect smoking status during early pregnancy. The smoking variable was categorized into nonsmokers and smokers. According to documentation in the medical records, women were classified as being admitted to the BFU and/or being assessed by a lactation consultant.
All data analysis was undertaken on de-identified data. Descriptive statistics were used to report frequencies, means, medians, and percentages. Univariate categorical analyses using the chi-square test or Fisher exact test, where appropriate, were conducted. The length of time between childbirth and the first domperidone dispensing was identified and presented as median number of days between childbirth to first domperidone dispensing. A quartile regression was performed to assess the median length of time from birth to first domperidone dispensing from January 2000 to July 2010. The number of repeat domperidone dispensings was calculated to investigate any change in the number of courses of domperidone received by each woman over the 10-year period.
Statistical analyses were performed using SPSS (version 19, Statistical Package for the Social Sciences, SPSS Inc, Chicago, IL) and STATA (version 11, Stata Corp, College Station, TX). Statistical significance was defined as a 2-sided P < .05. This project was approved by the Human Research Ethics Committees of The University of South Australia and the Women's and Children's Health Network in South Australia (465A).
Results

Database Audit
In total, 1605 (3.6%) women who delivered at the WCH between January 2000 and July 2010 were dispensed domperidone. Characteristics of women who were dispensed domperidone are shown in Table 1 , and characteristics of their infants are shown in Table 2 .
The number of women dispensed domperidone increased steadily over the 10-year period from less than 1% in 2000 to approximately 5% in 2010 (Figure 1 ). Over the 10-year period, there was no significant difference in the number of days between childbirth and first domperidone dispensing, with the majority of women (94%) were dispensed domperidone at least 4 or more days following childbirth. A further subanalysis demonstrated, however, that multiparous women were more likely to be dispensed domperidone within 3 days following childbirth compared to primiparous women (8% vs 4%; P < .01). Most of the women included in the audit were dispensed a single course of domperidone (81%), and the proportion of women receiving multiple courses of domperidone remained consistent over time. Mothers of preterm infants were more likely to receive a repeat domperidone dispensing than mothers of term infants (35% vs 10%; P < .01)
Medical Record Audit
Out of the 261 pairs of mother and infant medical records randomly selected, 215 pairs of medical records (82.4%) were reviewed. Forty-six pairs of medical records were not available for review. When maternal, or infant, or both medical records were unavailable, the pair of medical records was excluded.
For approximately one third (31%) of women dispensed domperidone, it was documented that they were admitted to the BFU, with a further 9% documented as being assessed by a lactation consultant. Mothers of preterm infants were more likely to be admitted to the BFU and/or be assessed by a lactation consultant than mothers of term infants (63% vs 19%; P < .01). In addition, primiparous women were more likely than multiparous women to be admitted to the BFU and/or be assessed by a lactation consultant (50% vs 25.8%; P < .01).
It was documented that a small percentage (5%) of women directly requested a prescription for domperidone, and a subanalysis demonstrated that multiparous women were more likely than primiparous women to directly request domperidone (9.0% vs 2.4%; P < .05). The most commonly dispensed direction over the 10-year period was the standardized domperidone dose-tapering schedule (96.4%).
Discussion
From January 2000 to July 2010, there was a steady increase in the number of women dispensed domperidone at the WCH, from less than 1% of all pregnancies in 2000 to approximately 5% in 2010. The infrequent use of domperidone between 2000 and 2002 may have been because of the preferred use of metoclopramide as the first-line treatment for managing insufficient breast milk supply during that time. The subsequent increase in domperidone use could be a result of a number of factors. First, the publication of a randomized controlled trial highlighting the effectiveness of domperidone in increasing milk supply in 2001 could explain the steady increase in domperidone use from 2002 onward. 12 Second, in response to the apparent increase in demand, a patient information sheet titled "Medications for increasing breast milk supply" was introduced at WCH in March 2003. The introduction of this patient information sheet may have led to increased dispensing as a result of increased patient and prescriber awareness of the use of domperidone for this indication. Third, it is possible that the increase in domperidone use could represent a switch from the use of metoclopramide to domperidone. Unfortunately, without data on the use of metoclopramide during these time periods, it is not possible to determine what effect a switch had on the usage patterns for domperidone.
Only half of the infants identified in the current study were preterm and/or admitted to the NICU or SCBU. This finding is despite the fact that the majority of previous Percentages do not add up to 100% because of missing data. b Percentages are calculated using the total number of women whose case notes were reviewed (N = 215) as the denominator. Journal of Human Lactation 29 (1) studies evaluating the use of domperidone as a galactogogue were composed of mothers of infants who were preterm and/ or admitted to a NICU. 3, 9, 12 The standardized domperidone dose-tapering schedule, introduced in 2005, was the most commonly used direction at the WCH, with the majority of women prescribed domperidone for a total of 12 days. Previously published literature provides inconsistent evidence regarding the most appropriate dose, duration, population, and time to initiate domperidone treatment, making it difficult to generate clear, evidence-based guidelines for the use of domperidone as a galactogogue. However, anecdotal evidence and clinical experiences recommended taking domperidone for at least 6 weeks in order to observe its effectiveness. 18 Therefore, it could be questioned whether the frequently used fixed dosetapering 12-day course is sufficient for evaluating whether domperidone would be effective in increasing milk production and supply. This issue is further highlighted by the fact that more than 30% of mothers who delivered preterm infants received more than 1 treatment course of domperidone, suggesting longer initial treatment courses could be required in certain situations to ensure maximal effectiveness.
Anecdotally, a reduction in the average length of a postnatal hospital stay at the WCH could be expected to result in an increased number of women dispensed domperidone earlier following delivery. However, the number of days between delivery and first domperidone dispensing did not change over the 10-year period. Given that 2 or 3 days is required for lactation to become well established, 19 the use of domperidone within the first 3 days following delivery could be considered inappropriate. It is positive that, of the women identified in this audit who were dispensed domperidone, only a small number (6%) were dispensed domperidone within the first 3 days following delivery. However, as it was documented that only a third of these women who were dispensed domperidone within 3 days following delivery were admitted to the BFU and/or saw a lactation consultant, it raises concerns as to whether women are being dispensed domperidone prior to the trial of appropriate nonpharmacological interventions to increase milk production and supply.
It is interesting to note that multiparous women were more likely to receive a domperidone dispensing within 3 days following delivery compared to primiparous women. It could be speculated that multiparous women with lactation difficulties in a previous pregnancy received domperidone treatment earlier because they expected to experience similar breastfeeding difficulties and requested domperidone earlier. Conversely, primiparous women will have to first attempt breastfeeding themselves prior to realizing they have difficulties breastfeeding, 20 and they may also be naive to the existence of domperidone and its use as a galactogogue. This finding is also in accordance with the current finding that multiparous women were more likely than primiparous women to directly request domperidone.
It is clear that domperidone should not be used as a substitute for, or as an alternative to, effective nonpharmacological breastfeeding support and encouragement. It is imperative for women who have breastfeeding difficulties to be assessed by a lactation consultant and/or be admitted to the BFU to ensure modifiable risk factors of poor breastfeeding are addressed prior to the prescription of any galactogogue. It is of concern that only 40% of mothers dispensed domperidone were admitted to the BFU and/or received specialist advice from a lactation consultant. However, it is possible that the number of women who received advice from a lactation consultant was underestimated, because of poor documentation Year in medical records and/or the possibility that some women were assessed by a lactation consultant outside of the WCH. There are several limitations in the current study. First, this study relied on WCH pharmacy dispensing data to determine domperidone use. The total use of domperidone among the cohort of women in the current study is likely to be underestimated, as some women may have been prescribed and dispensed domperidone outside of the WCH. Without prospectively following a cohort of women after delivery, there is no way to identify how domperidone is being prescribed in the community setting. Second, not all medical records identified in the original random sampling procedure were available for examination, and the quality of data collected was dependent on the quality of documentation in medical records. In particular, not all of the original prescriptions could be found in the medical records. Third, although prescribing of domperidone at the hospital is limited to medical doctors, we did not collect data on individual prescribers, which limited our ability to analyze data according to specific prescriber characteristics.
This audit of domperidone use as a galactogogue highlights a number of key areas for future research. There is a clear need to ensure all women have access to appropriate nonpharmacological support and advice regarding breastfeeding. Furthermore, there is a need to identify the most effective time to initiate domperidone treatment after delivery, recognizing that this time may be different for primiparous and multiparous women. In addition, further evaluation is required on the most appropriate dose and duration of treatment and whether dose tapering is required and how it should be undertaken. It would also be useful to investigate why some women do and do not respond to treatment with domperidone, which may allow further medication tailoring.
Conclusion
In conclusion, the retrospective audit at WCH indicates an overall increase in the percentage of mothers being dispensed domperidone in the last 10 years. With a lack of clinical evidence to guide use, current practice appears to be based on anecdotal evidence, highlighting the need for welldesigned randomized controlled trials to support evidencebased practice on the use of domperidone as a galactogogue.
